Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies. (14th April 2022)

• Record Type: Journal Article
• Authors: Yetmar, Zachary A; Khodadadi, Ryan B; Seville, Maria Teresa; Brumble, Lisa; O'Horo, John C; Ganesh, Ravindra; Razonable, Raymund R
• Is Part Of: Open forum infectious diseases. Volume 9:Number 7(2022)
• Publication Date: 2022-04-14
• Subjects: anti-CD20 -- COVID-19 -- monoclonal antibody -- rituximab -- SARS-CoV-2; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac204
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.